Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07222436Recruiting
Blood test for high-risk prostate cancer
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT07227961Recruiting
Sarcoma surgery and recovery study using a phone app
This study uses a phone app to track how well people recover after surgery for bone or soft tissue sarcoma. It may help doctors understand how to improve movement and quality of life after treatment.
Phoenix, ArizonaAges 18 years+ - NCT07229768RecruitingEarly Phase 1
Study of 177Lu-CTR-FAPI for advanced solid tumors
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
ShanghaiAges 18–85 - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT07239063Recruiting
Lung and colorectal cancer tissue test study
This study checks a new way to prepare large tissue samples from lung or colorectal cancer for faster testing. It may help improve how tumors are analyzed.
Guangzhou, GuangdongAges Any age - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT04925089Recruiting
Testing biomarkers in localized soft tissue cancer before surgery
This study looks at lab biomarkers (signs in tumor tissue) in people with localized leiomyosarcoma. It also requires treatment with chemotherapy before surgery to see if the information from tumor samples can help guide care.
Ann Arbor, MichiganAges Any age - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07262138Recruiting
Active monitoring for older women with early breast cancer
This trial studies whether active monitoring (watchful waiting) can be a safe option instead of immediate surgery or other treatments for women 70 and older who have a small, slow-growing type of breast cancer. If you join, you will not have surgery or other treatments right away, but your cancer will be closely watched.
Pittsburgh, PennsylvaniaAges 70 years+ - NCT07263438RecruitingPhase 2
Trimipramine, atezolizumab, and bevacizumab for recurrent glioblastoma
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Basel, BaselAges 18 years+ - NCT07263594RecruitingPhase 1/Phase 2
Study of DB-1324 for advanced stomach or bowel cancers
This trial tests a new drug called DB-1324 for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. It targets a protein called CDH17 on cancer cells to slow or shrink the tumor.
Port Saint Lucie, FloridaAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07293676Recruiting
Massage and vibration for low back disc pain
This study tests if hand-held massage tools (IASTM) and gentle vibration therapy can reduce pain, improve movement, and lessen fear of movement in people with a bulging disc in their lower back. It is for adults aged 30-60 with moderate to severe pain lasting 3 months or longer.
IstanbulAges 30–60 - NCT07327684Recruiting
Imaging brown fat activity with ultrasound
This study uses a special camera (photoacoustic/ultrasound) to look at a type of fat called 'brown fat' that helps your body burn energy. You may be able to join as a healthy volunteer or if you have a condition like type 2 diabetes or PCOS.
BeijingAges 18–80 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT07338006Recruiting
Chest wall reconstruction study
This trial studies patients who need surgery to rebuild part of their chest wall after a defect. It looks at how well different reconstruction methods work, especially for larger defects that can't be simply closed.
Lahore, Punjab ProvinceAges 18 years+ - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT04837547RecruitingPhase 1
Personalized cell therapy for childhood cancer
This trial tests a new, personalized cell therapy for children with high-risk neuroblastoma or DIPG (a type of brain tumor) that has come back or is hard to treat. It uses the patient's own tumor to create a treatment that might work better for them.
Gainesville, FloridaAges 1–30
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,319 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.